

PRESS RELEASE
11 October 2024 10:00:00 CEST



Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE

On October 4th, Dr. Dag Sandblom, MD, Consultant Urologist from Sweden, presented short-term results and long-term durability of CoreTherm® treatments at the Emirates International Urological Conference 2024, held in Dubai, United Arab Emirates. The data were compiled from patients treated in Sweden at Capio Specialistcenter Solna, Region Stockholm, and Capio Läkargruppen Örebro.

Since August 2020, a total of 720 patients have undergone CoreTherm® treatment at these centers. This first analysis included 132 patients, demonstrating effective symptom relief with an IPSS (International Prostate Symptom Score) reduction from 24.6 to 8.2. The Bother Score (the quality-of-life impairment domain of the IPSS) was reduced from 4.2 to 1.6, and residual urine was significantly reduced. Approximately 70% of patients were catheter-free after 4 weeks, and 80% were satisfied with the treatment results after 4 months. The favourable outcomes observed after 4 months appear to remain stable throughout the 12–36-month follow-up period.

The average age of the patients was 75.6 years (ranging from 52 to 96 years), with an average prostate volume of 60 cc (ranging from 24 to 290 cc). The average treatment time was 9 minutes.

The authors of the abstract concluded that transurethral microwave thermotherapy with CoreTherm® provides durable symptom relief and may save older men from permanent catheter use.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About CoreTherm®

CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPE). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.



PRESS RELEASE
11 October 2024 10:00:00 CEST

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,600 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE